|Bid||2.95 x 4000|
|Ask||3.15 x 1400|
|Day's Range||2.99 - 3.29|
|52 Week Range||2.99 - 10.00|
|Beta (3Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.32|
Aduro Biotech, Inc. (ADRO) today announced presentation of preliminary data from its ongoing Phase 1 dose-finding study of ADU-S100 (MIW815), a novel STING (stimulator of interferon genes) pathway activator, at SITC's 33rd Annual Meeting in Washington, D.C. Aduro and collaborator Novartis embarked on this first-in-human trial (see www.clinicaltrials.gov, identifier NCT02675439) as an important first step in characterizing the safety profile and mechanism of ADU-S100 and its ability to activate the STING pathway. The Phase 1 dose escalation and dose expansion clinical trial is designed to evaluate the safety, tolerability and clinical activity of ADU-S100 in patients with advanced, metastatic treatment-refractory solid tumors or lymphomas.
Aduro Biotech, Inc. (ADRO) today announced that the company will host and webcast an investor event on Friday, November 9, 2018 at 6:30 p.m. Eastern Time in Washington, D.C. The event will feature special guest speaker Jason J. Luke, M.D., FACP, Assistant Professor of Medicine at the University of Chicago and a principal investigator for the Phase 1 dose-finding studies of ADU-S100 (MIW815), a novel STING (stimulator of interferon genes) pathway activator. The archived webcast will remain available for replay on Aduro’s website for 30 days.
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.
Aduro Biotech (ADRO) delivered earnings and revenue surprises of 6.45% and -33.21%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
BERKELEY, Calif., Oct. 30, 2018 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the third quarter ended September 30, 2018. Net loss for the third.
Aduro Biotech, Inc. (ADRO) today announced preclinical data for its first-in-class anti-APRIL antibody BION-1301 supporting its use in the treatment of IgA nephropathy (IgAN) at the American Society of Nephrology (ASN) Kidney Week 2018 in San Diego, CA. IgAN is a progressive kidney disease characterized by an autoimmune antibody response against endogenous IgA. Preclinical studies demonstrated that BION-1301 binds to a specifically defined epitope on APRIL, resulting in complete blockade of APRIL induced receptor activation, and is expected to lead to suppression of IgA and the autoimmune response to IgA associated with the disease.
Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aduro Biotech, Inc. (ADRO) today announced that four separate abstracts from its research and development portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C. from November 7-11, 2018. Preliminary clinical data from the ongoing Phase 1 dose-finding study evaluating ADU-S100 (MIW815), an intratumoral STING agonist in patients with advanced solid tumors or lymphomas, were accepted for presentation on November 9, 2018. “We look forward to sharing preliminary clinical data from the dose escalation portion of the monotherapy trial which provides an initial understanding of the potential role of ADU-S100 in the treatment of cancer and which contribute to the broader scientific understanding of the STING pathway,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro Biotech.
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that are intended to transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases.
Aduro Biotech, Inc. (ADRO) today announced that Natalie R. Sacks, M.D. has resigned from her position as the company’s chief medical officer effective October 1, 2018. “On behalf of the management team and Board of Directors, I’m grateful for the significant contributions Natalie made over the past three years and we wish her the best in her next endeavor,” commented Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “During her tenure, Natalie has played an integral role in defining the development strategy for our lead STING agonist ADU-S100 and for our anti-APRIL antibody BION-1301, two first-in-class assets that have potential to impact the treatment landscape for patients with a myriad of serious diseases.
Aduro BioTech (ADRO) needs investors to pay close attention to the stock based on moves in the options market lately.
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. Aduro BioTech’s insiders have divested from 53.11k sharesRead More...
Aduro Biotech, Inc. (ADRO) today announced the publication of a peer reviewed paper in Leukemia authored by scientists from the Dana Farber Cancer Institute and Aduro as part of their ongoing collaboration to study the role of APRIL (A PRoliferation Inducing Ligand) in multiple myeloma (MM). The authors profile the impact that APRIL, acting through its receptor TACI (transmembrane activator and cyclophilin ligand interactor), has on immune regulatory T cells (Tregs) in MM. The paper further reports that APRIL binding to TACI contributes to the immunosuppressive and treatment resistant MM bone marrow microenvironment, an effect that could potentially be mitigated by anti-APRIL antibody, BION-1301.
Aduro Biotech, Inc. (ADRO) today announced that preclinical data for its first-in-class anti-APRIL antibody BION-1301 was presented at the 5th European Congress of Immunology in Amsterdam, The Netherlands. Data from the preclinical studies demonstrated that BION-1301 was well-tolerated. In addition, pharmacological activity of BION-1301 binding to APRIL (A Proliferation-Inducing Ligand), a ligand for the receptors BCMA (B cell maturation antigen) and TACI (transmembrane activator and cyclophilin ligand interactor), was established in a dose-dependent fashion.
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aduro Biotech, Inc. (ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 20th Annual H.C. Wainwright Global Investment Conference in New York, NY on Wednesday, September 5, 2018 at 1:45pm Eastern Time. To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro's website at www.aduro.com. Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that are intended to transform the treatment of challenging diseases.
NEW YORK, Aug. 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearwater ...
Aduro Biotech (ADRO) delivered earnings and revenue surprises of 6.06% and -29.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Berkeley, California-based company said it had a loss of 31 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on ADXS sign up now at www.wallstequities.com/registration. On Wednesday, July 25, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories.